Biopharma Team Bolsters Ranks for Safer Drug-Making Collabs
Published Date: 1/2/2026
Notice
Summary
The Biopharmaceutical Manufacturing Preparedness Consortium (BIOMAP) just added a bunch of new members from all over the U.S. and Canada to help boost their research teamwork. This update keeps their special legal protections against big lawsuits in place, so they can focus on making better medicines without worrying about costly legal battles. If you’re part of this group or interested in biopharma, keep an eye out because membership is still open and changes might keep coming!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Antitrust Damage Limit Extended for BIOMAP
On April 10, 2025 BIOMAP filed notifications to extend the protections of the National Cooperative Research and Production Act of 1993 that limit antitrust plaintiffs to recovering actual damages under specified circumstances. If you are a member of the BIOMAP consortium, those statutory limits on antitrust recovery apply to the venture as disclosed in that filing.
New Members Added to BIOMAP Consortium
The notice lists new parties added to the BIOMAP consortium as of the filing, including CytoImmune Therapeutics, Inc. (Duarte, CA); Ecolab, Inc. (Philadelphia, PA); Evoworks Bio (Cambridge, MA); Sterling Wisconsin LLC (Germantown, WI); University of Louisiana at Lafayette (Lafayette, LA); 375Sciences (Summit Point, WV); Ambient Biosciences (Ann Arbor, MI); CODEXIS, Inc. (Redwood City, CA); Jamison Case (Batesville, AR); WellPact LLC (Roaring Spring, PA); and others named in the notice. These entities have been added as parties to the venture.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-19100, United States of America, et al. v. RealPage, Inc., et al.; Proposed Final Judgment and Competitive Impact Statement
The U.S. government is stopping Pinnacle Property Management from using RealPage’s pricing software that shares sensitive info with landlords, which broke competition rules. Pinnacle must also set up new rules to keep things fair and help the government watch over this. People have 60 days to share their thoughts before the court makes it official.
2026-18136, United States v. KKR & Co. Inc., et al.; Proposed Final Judgment and Competitive Impact Statement
The U.S. government caught KKR & Co. Inc. for not properly reporting important business deals before they happened—16 times! Now, KKR has to pay a huge $250 million fine within 30 days to settle the case. This action helps keep big business honest and fair for everyone.
2026-16850, United States of America, et al. v. CRH PLC, et al. Proposed Final Judgment and Competitive Impact Statement
The U.S. government and Tennessee are stopping APAC-Tennessee from buying Standard Construction Group because it could hurt competition. To fix this, both companies must sell two key facilities in Memphis and Millington, Tennessee. People have 60 days to share their thoughts before the deal is finalized, keeping the market fair and open.
2026-16112, United States et al. v. Cal-Maine Foods, Inc. et al.; Proposed Final Judgment and Competitive Impact Statement
2026-14903, United States, et al. v. OhioHealth Corporation; Proposed Final Judgment and Competitive Impact Statement
The U.S. government and Ohio are taking on OhioHealth Corporation for using sneaky contract rules that stop insurers from offering cheaper health plans. OhioHealth must now remove these rules and promise not to use them again, helping more budget-friendly options reach patients. People have 60 days to share their thoughts before the court makes it official.
2026-14935, United States v. Edwards LifeSciences Corp. and Genesis MedTech Group Limited; Proposed Final Judgment and Competitive Impact Statement
The U.S. government says Edwards LifeSciences broke the rules when it bought JC Medical from Genesis MedTech. Edwards must pay $10 million, Genesis pays $2 million, and Edwards has to get approval before buying any company working on special heart valve devices in the U.S. This keeps the market fair and protects competition in heart health tech.
Previous / Next Documents
Previous: 2025-24164, Combined Notice of Filings #1
The Federal Energy Regulatory Commission got a bunch of filings from energy companies about their power status and market control in different regions. These filings mostly update how much power companies control and could affect electricity prices or competition. If you want to comment, mark your calendar—deadlines range from mid-January to late February 2026.
Next: 2025-24166, Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium
The Medical CBRN Defense Consortium (MCDC) just added seven new members and said goodbye to one. This update keeps their special legal protections against big lawsuits in place while they work together on medical defense research. If you’re part of this group or interested in their work, expect more membership updates soon—no money changes or project shifts right now!